Lannett Company, Inc. today announced it has received approval from the U.S. FDA for the companys supplemental Abbreviated New Drug Application (ANDA) of Phentermine Hydrochloride Capsules 30 mg. The company expects to commence marketing this product immediately. Read More.

Lannett Company, Inc. today reported its financial results for the fiscal 2008 first quarter ended on September 30, 2007.
Read More.

View the Report.

Lannett Company is pleased to comment on the recent FDA Announcement regarding Levothyroxine Sodium. The FDA issued a public notice adopting the recommendation of an advisory panel of endocrinologists tightening the label specification for potency range to 95-105%. Read More.

Lannett Company, Inc. today announced it has filed its audited financial results on From 10-K for the year ended June 30, 2007 with the Securities and Exchange Commission.
Read More.

Lannett Company, Inc. today announced it has received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Baclofen 10mg tablets, bolstering the company's existing product offering of Baclofen 20mg tablets.
Read More.

Lannett Company, Inc. today announced that Arthur Bedrosian, president and chief executive officer, will present at FTN Midwest HealthCare Conference on June 6, 2007.
Read More.

View the Report

View the Report.

Lannett Company, Inc. today reported its financial results for the fiscal 2007 third quarter ended on March 31, 2007.
Read More.

Lannett Company, Inc. today announced that Arthur Bedrosian, president and chief executive officer, will present at 2007 UBS Global Generic and Specialty Pharmaceuticals Conference on May 8, 2007.
Read More.

Lannett Company, Inc. today announced it has received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Danazol Capsules 50mg and 100mg.
Read More.

Lannett Company, Inc. today announced it has acquired a privately-owned manufacturer/supplier of bulk active pharmaceutical ingredients (API). Financial terms of the agreement were not disclosed.
Read More.

Lannett Company, Inc. today reported its financial results for the fiscal 2007 second quarter six months ended on December 31, 2006.
Read More.

Lannett Company, Inc announced today that it will shortly commence distributing Meloxicam, the generic equivalent of Boehringer Ingelheim's Mobic.
Read More.

Lannett Company, Inc announced today the signing of a supply agreement with Banner Pharmacaps, Inc.
Read More.

Lannett Company, Inc announced today that it has signed a research agreement with Pharmaseed Bioservices, a drug development company based in Israel.
Read More.